This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
11-13 November 2025
Congress Center BaselBasel, Switzerland

Jonathan Hall, PhD
Full Professor at ETH Zurich
Speaker

Profile

Jonathan Hall received his Ph.D. in chemistry at Imperial College in London. He did post-doctoral work at L’Université Loius Pasteur in Strasbourg and at Harvard University in Cambridge. He joined the nucleic acids section at Ciba Central Research Labs in Basel in 1992 and in 2000 he headed the group. In the following six years his group established high-throughput oligonucleotide synthesis and genome-wide screening using siRNAs. Together with the Neuroscience Department they developed methods to use RNAi in vivo which resulted in therapeutic effects of siRNAs in rat models of pain. In 2007 he joined the Institute of Pharmaceutical Sciences at the ETH as Professor of Pharmaceutical Chemistry and in 2012 he served as Chairman of the Institute. A principal goal of his group is to help bring RNA as a drug and a target into mainstream pharmaceutical research.

Agenda Sessions

  • Future Directions for Medicinal Chemistry in the Field of Oligonucleotide Therapeutics

    08:05